FDA Approves BESREMi for Adults with Essential Thrombocythemia, a Rare Blood Cancer

The U.S. Food and Drug Administration (FDA) has approved BESREMi® (ropeginterferon alfa-2b-njft) for the treatment of adults with essential thrombocythemia (ET), a rare chronic blood cancer characterized by an overproduction of platelets. This marks the first new FDA-approved treatment for ET in nearly three decades and is approved regardless of genotype or disease status, including for newly diagnosed patients.